Erratum: The gp41 epitope, QARVLAVERY, is highly conserved and a potent inducer of IgA that neutralizes HIV-1 and inhibits viral transcytosis (Mucosal Immunology (2011) 4 (539-553) DOI:10.1038/mi.2011.21);The gp41 epitope, QARVLAVERY, is highly conserved and a potent inducer of IgA that neutralizes HIV-1 and inhibits viral transcytosis

Mucosal Immunology

Volumn 4, Issue 5, 2011, Pages 539-553

  Jain, S ^a   Rosenthal, K L ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLUTAMINYLALANYLARGINYLVALYLLEUCYLALANYLVALYLGLUTAMYLARGINYLTYROSINE; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCYTOSIS; VIRUS INDUCTION; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

EID: 84860389036     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2011.44     Document Type: Erratum

References (109)

1. Tomaras, G. D. & Haynes, B. F. HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr. Opin. HIV AIDS 4, 373-379 (2009).
2. Moore, P. L. et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 80, 2515-2528 (2006). (Pubitemid 43271557)
3. Moore, P. L. et al. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 5, e1000598 (2009).
4. Rong, R. et al. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 5, e1000594 (2009).
5. Flynn, N. M., Forthal, D. N., Harro, C. D., Judson, F. N., Mayer, K. H. & Para, M. F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654-665 (2005).
6. Lee, D. et al. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J. Infect. Dis. 190, 903-907 (2004). (Pubitemid 39120966)
7. Goulder, P. J. et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3, 212-217 (1997). (Pubitemid 27064707)
8. Allen, T. M. et al. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J. Virol. 78, 7069-7078 (2004) (Pubitemid 38781545)
9. zur Megede, J. et al. A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques. AIDS Res. Hum. Retroviruses 24, 1103-1116 (2008).
10. Suh, Y. S. et al. Prolonged survival of vaccinated macaques after oral SIVmac239 challenge regardless of viremia control in the chronic phase. Vaccine 26, 6690-6698 (2008).
11. Zwick, M. B. et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75, 10892-10905 (2001). (Pubitemid 33034579)
12. Zwick, M. B. et al. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J. Virol. 75, 12198-12208 (2001). (Pubitemid 33115893)
13. Zhou, T. et al. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template. Chem. Biol. Drug Des. 75, 18-28 (2010).
14. Corti, D. et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5, e8805 (2010).
15. Pancera, M. et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 84, 8098-8110 (2010).
16. Jain, S., Patrick, A. J. & Rosenthal, K. L. Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen. Vaccine 28, 7070-7080 (2010).
17. Ura, T. et al. Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1. J. Gene Med. 11, 139-149 (2009).
18. Lapelosa, M., Arnold, G. F., Gallicchio, E., Arnold, E. & Levy, R. M. Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected]. J. Mol. Biol. 397, 752-766 (2010).
19. Liao, M., Lu, Y., Xiao, Y., Dierich, M. P. & Chen, Y. Induction of high level of specific antibody response to the neutralizing epitope ELDKWA on HIV-1 gp41 by peptide-vaccine. Peptides 21, 463-468 (2000). (Pubitemid 30261562)
20. Haynes, B. F. et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906-1908 (2005). (Pubitemid 40941873)
21. Matyas, G. R., Beck, Z., Karasavvas, N. & Alving, C. R. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim. Biophys. Acta. 1788, 660-665 (2009).
22. Verkoczy, L. et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc. Natl Acad. Sci. USA 107, 181-186 (2010).
23. Tyler, D. S. et al. Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J. Immunol. 145, 3276-3282 (1990).
24. Lambotte, O. et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23, 897-906 (2009).
25. Gomez-Roman, V. R. et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174, 2185-2189 (2005). (Pubitemid 40223963)
26. Hessell, A. J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101-104 (2007). (Pubitemid 47373775)
27. Forthal, D. N. & Moog, C. Fc receptor-mediated antiviral antibodies. Curr. Opin. HIV AIDS 4, 388-393 (2009).
28. Duval, M., Posner, M. R. & Cavacini, L. A. A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils. J. Virol. 82, 4671-4674 (2008). (Pubitemid 351563705)
29. Broliden, K. et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol. Lett. 79, 29-36 (2001). (Pubitemid 32938205)
30. Clerici, M. et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS 16, 1731-1741 (2002).
31. Devito, C. et al. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J. Acquir. Immune Defic. Syndr. 30, 413-420 (2002). (Pubitemid 34857316)
32. Devito, C. et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 14, 1917-1920 (2000).
33. Mazzoli, S. et al. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J. Infect. Dis. 180, 871-875 (1999). (Pubitemid 29411381)
34. Pastori, C. et al. HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket. J. Biol. Regul. Homeost. Agents 14, 15-21 (2000). (Pubitemid 32288559)
35. Devito, C. et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J. Immunol. 165, 5170-5176 (2000).
36. Tudor, D. et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol. 2, 412-426 (2009).
37. Wright, A., Lamm, M. E. & Huang, Y. T. Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A. J. Virol. 82, 11526-11535 (2008).
38. Hocini, H. et al. High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res. Hum. Retroviruses 13, 1179-1185 (1997). (Pubitemid 27408075)
39. Belec, L. et al. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J. Infect Dis. 184, 1412-1422 (2001). (Pubitemid 33108855)
40. Alfsen, A., Iniguez, P., Bouguyon, E. & Bomsel, M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J. Immunol. 166, 6257-6265 (2001). (Pubitemid 32440758)
41. Bomsel, M. et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 9, 277-287 (1998). (Pubitemid 28400041)
42. Huang, Y. T., Wright, A., Gao, X., Kulick, L., Y a n, H. & Lamm, M. E. Intraepithelial cell neutralization of HIV-1 replication by IgA. J. Immunol. 174, 4828-4835 (2005).
43. Nguyen, M. et al. HIV-specific antibodies but not t-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia. J. Acquir. Immune Defic. Syndr. 42, 412-419 (2006). (Pubitemid 44050887)
44. Lopalco, L. et al. Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. J. Gen. Virol. 86, 339-348 (2005). (Pubitemid 40227945)
45. Kaul, R. et al. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 13, 23-29 (1999). (Pubitemid 29078060)
46. Horton, R. E. et al. Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV. AIDS Res. Hum. Retroviruses 25, 83-92 (2009).
47. Ebersold, A. et al. Human and murine monoclonal antibodies directed against a conserved sequence from gp41 (aa583-599) of human immunodeficiency virus type 1. Res. Virol. 143, 179-191 (1992).
48. Klasse, P. J., Pipkorn, R. & Blomberg, J. A cluster of continuous antigenic structures in the transmembrane protein of HIV-1: individual patterns of reactivity in human sera. Mol. Immunol. 28, 613-622 (1991).
49. Vanini, S., Longhi, R., Lazzarin, A., Vigo, E., Siccardi, A. G. & Viale, G. Discrete regions of HIV-1 gp41 defined by syncytia-inhibiting affinity-purified human antibodies. AIDS 7, 167-174 (1993). (Pubitemid 23091285)
50. Neurath, A. R., Strick, N. & Lee, E. S. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19-to 36-residue) synthetic peptides. J. Gen. Virol. 71 (Pt 1), 85-95 (1990). (Pubitemid 20046013)
51. Cai, L., Balogh, E. & Gochin, M. Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors. Antimicrob. Agents Chemother. 53, 2444-2449 (2009).
52. Klasse, P. J., Pipkorn, R. & Blomberg, J. Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects. Proc. Natl Acad. Sci. USA 85, 5225-5229 (1988).
53. Wexler-Cohen, Y., Johnson, B. T., Puri, A., Blumenthal, R. & Shai, Y. Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178. J. Biol. Chem. 281, 9005-9010 (2006). (Pubitemid 43864612)
54. Goudsmit, J. Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts. AIDS 2 (Suppl 1), S41-S45 (1988). (Pubitemid 19042837)
55. Klasse, J., Pipkorn, R., Blomberg, J., Han, K. H., Hilton, B. & Ferretti, J. A. Three-dimensional structure and antigenicity of transmembrane-protein peptides of the human immunodeficiency virus type 1. Effects of a neutralization-escape substitution. FEBS Lett. 323, 68-72 (1993). (Pubitemid 23158334)
56. Schulz, T. F., Jameson, B. A., Lopalco, L., Siccardi, A. G., Weiss, R. A. & Moore, J. P. Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins? AIDS Res. Hum. Retroviruses 8, 1571-1580 (1992).
57. Almond, N. M., Worms, M. J., Harnett, W. & Parkhouse, R. M. Variation in class-specific humoral immune responses of different mouse strains to microfilariae of Dipetalonema viteae. Parasitology 95 (Pt 3), 559-568 (1987).
58. Graham, B. S. et al. Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination. Mucosal Immunol. 3, 475-486 (2010).
59. Lu, B. et al. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice. Immunology 130, 254-261 (2010).
60. Avramidis, N., Victoratos, P., Yiangou, M. & Hadjipetrou-Kourounakis, L. Adjuvant regulation of cytokine profile and antibody isotype of immune responses to Mycoplasma agalactiae in mice. Vet. Microbiol. 88, 325-338 (2002). (Pubitemid 35245918)
61. Bessa, J. et al. Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J. Immunol. 183, 3788-3799 (2009).
62. He, B. et al. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J. Immunol. 176, 3931-3941 (2006). (Pubitemid 44264370)
63. Zhang, S., Cubas, R., Li, M., Chen, C. & Yao, Q. Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells. Mol. Immunol. 46, 1988-2001 (2009).
64. Yang, R. et al. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J. Immunol. 174, 7912-7919 (2005). (Pubitemid 40806301)
65. Gray, R. H. et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357, 1149-1153 (2001). (Pubitemid 32378686)
66. Mestecky, J. et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res. Hum. Retroviruses 20, 972-988 (2004). (Pubitemid 39369704)
67. Mestecky, J., Moldoveanu, Z., Smith, P. D., Hel, Z. & Alexander, R. C. Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. J. Reprod. Immunol. 83, 196-200 (2009).
68. Goodsell, A. et al. Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery. Immunology 123, 378-389 (2008). (Pubitemid 351171190)
69. Lehner, T. et al. Targeted lymph node immunization with simian immunodeficiency virus p27 antigen to elicit genital, rectal, and urinary immune responses in nonhuman primates. J. Immunol. 153, 1858-1868 (1994). (Pubitemid 24251131)
70. Lehner, T. et al. Mucosal model of genital immunization in male rhesus macaques with a recombinant simian immunodeficiency virus p27 antigen. J. Virol. 68, 1624-1632 (1994). (Pubitemid 24065728)
71. Stevceva, L. et al. Cervicovaginal lamina propria lymphocytes: phenotypic characterization and their importance in cytotoxic T-lymphocyte responses to simian immunodeficiency virus SIVmac251. J. Virol. 76, 9-18 (2002). (Pubitemid 33138987)
72. Devito, C. et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J. Immunol. 173, 7078-7089 (2004). (Pubitemid 39541098)
73. Walker, L. M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
74. Xiao, P. et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 84, 7161-7173 (2010).
75. Russell, M. W., Sibley, D. A., Nikolova, E. B., Tomana, M. & Mestecky, J. IgA antibody as a non-inflammatory regulator of immunity. Biochem. Soc. Trans. 25, 466-470 (1997). (Pubitemid 27260853)
76. Pasquier, B. et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 22, 31-42 (2005). (Pubitemid 40143449)
77. Lester, R. T. et al. HIV-1 RNA dysregulates the natural TLR response to subclinical endotoxemia in Kenyan female sex-workers. PLoS One 4, e5644 (2009).
78. Lester, R. T. et al. Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS 22, 685-694 (2008). (Pubitemid 351450636)
79. Card, C. M., McLaren, P. J., Wachihi, C., Kimani, J., Plummer, F. A. & Fowke, K. R. Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4(+)CD25(+) FOXP3(+) regulatory T cells. J. Infect. Dis. 199, 1318-1322 (2009).
80. Horton, R. E. et al. A comparative analysis of gene expression patterns and cell phenotypes between cervical and peripheral blood mononuclear cells. PLoS One 4, e8293 (2009).
81. Lawn, S. D., Butera, S. T. & Folks, T. M. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin. Microbiol. Rev. 14, 753-777, table of contents (2001).
82. Brenchley, J. M. & Douek, D. C. The mucosal barrier and immune activation in HIV pathogenesis. Curr. Opin. HIV AIDS 3, 356-361 (2008). (Pubitemid 351521021)
83. Brown, W. R. & Kloppel, T. M. The liver and IgA: immunological, cell biological and clinical implications. Hepatology 9, 763-784 (1989). (Pubitemid 19123527)
84. Li, Y. et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 83, 1045-1059 (2009).
85. Tomaras, G. D. et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82, 12449-12463 (2008).
86. Gray, E. S. et al. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J. Virol. 83, 8925-8937 (2009).
87. McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N. & Haynes, B. F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10, 11-23 (2010).
88. Alam, S. M. et al. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 82, 115-125 (2008). (Pubitemid 350309129)
89. Macpherson, A. J., Gatto, D., Sainsbury, E., Harriman, G. R., Hengartner, H. & Zinkernagel, R. M. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 288, 2222-2226 (2000). (Pubitemid 30429609)
90. Alugupalli, K. R., Leong, J. M., Woodland, R. T., Muramatsu, M., Honjo, T. & Gerstein, R. M. B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity 21, 379-390 (2004). (Pubitemid 39208339)
91. Hsu, M. C., Toellner, K. M., Vinuesa, C. G. & Maclennan, I. C. B cell clones that sustain long-term plasmablast growth in T-independent extrafollicular antibody responses. Proc. Natl Acad. Sci. USA 103, 5905-5910 (2006).
92. Whitmore, A. C., Neely, H. R., Diz, R. & Flood, P. M. Rapid induction of splenic and peritoneal B-1a cells in adult mice by thymus-independent type-2 antigen. J. Immunol. 173, 5406-5414 (2004). (Pubitemid 39392124)
93. Martin, F., Oliver, A. M. & Kearney, J. F. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 14, 617-629 (2001). (Pubitemid 32520872)
94. Martin, F. & Kearney, J. F. B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a " natural immune memory ". Immunol. Rev. 175, 70-79 (2000). (Pubitemid 30427157)
95. Stoel, M. et al. Restricted IgA repertoire in both B-1 and B-2 cell-derived gut plasmablasts. J. Immunol. 174, 1046-1054 (2005). (Pubitemid 40094301)
96. Baumgarth, N., Herman, O. C., Jager, G. C., Brown, L. E., Herzenberg, L. A. & Chen, J. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J. Exp. Med. 192, 271-280 (2000). (Pubitemid 30470309)
97. Choi, Y. S. & Baumgarth, N. Dual role for B-1a cells in immunity to influenza virus infection. J. Exp. Med. 205, 3053-3064 (2008).
98. Kaminski, D. A. & Stavnezer, J. Enhanced IgA class switching in marginal zone and B1 B cells relative to follicular/B2 B cells. J. Immunol. 177, 6025-6029 (2006). (Pubitemid 44628816)
99. Kamga, I. et al. Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J. Infect. Dis. 192, 303-310 (2005). (Pubitemid 40993400)
100. Hosmalin, A. & Lebon, P. Type I interferon production in HIV-infected patients. J. Leukoc. Biol. 80, 984-993 (2006). (Pubitemid 44646304)
101. Poli, G., Orenstein, J. M., Kinter, A., Folks, T. M. & Fauci, A. S. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science 244, 575-577 (1989). (Pubitemid 19140811)
102. Chen, Y. H. & Dierich, M. P. A common epitope on gp41, IFN-alpha and IFN-beta induces protective activity. Immunol. Today 19, 586-587 (1998).
103. Chen, Y. H., Xiao, Y. & Dierich, M. P. HIV-1 gp41 and type I interferon: sequence homology and biological as well as clinical implications. Immunol. Res. 22, 61-66 (2000). (Pubitemid 30487441)
104. Estes, D. M., T u o, W., Brown, W. C. & Goin, J. Effects of type I/type II interferons and transforming growth factor-beta on B-cell differentiation and proliferation. Definition of costimulation and cytokine requirements for immunoglobulin synthesis and expression. Immunology 95, 604-611 (1998). (Pubitemid 28559154)
105. Thompson, J. M., Whitmore, A. C., Staats, H. F. & Johnston, R. The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine 26, 4998-5003 (2008).
106. Chang, J. J. & Altfeld, M. Innate immune activation in primary HIV-1 infection. J. Infect. Dis. 202 (Suppl 2), S297-S301 (2010).
107. Platt, E. J., Wehrly, K., Kuhmann, S. E., Chesebro, B. & Kabat, D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72, 2855-2864 (1998). (Pubitemid 28175522)
108. Montefiori, D. C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485, 395-405 (2009).
109. Bomsel, M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 3, 42-47 (1997). (Pubitemid 27019139)